Through promoting the proliferation and activity of CD8+ T cells and making tumor cells sensitive to T-cell recognition, class I histone deacetylase (HDAC) inhibitors damage BC cell growth (McCaw TR et al., 2019). Here, HDAC9 is linked to breast cancer.